SU101 tyrosine kinase agent: Began a Phase I dose-escalation trial

SUGEN Inc. (SUGN), Redwood City, Calif. Product: SU101 tyrosine kinase agent, which blocks signaling at the receptor for platelet-derived growth factor Indication: Malignant glioma Status: Began a Ph...